NCT07451002
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
- Locations
-
- Centre Francois Baclesse Caen, France
Clinical trial condition
Metastatic Hormone-sensitive Prostate Cancer
Explore clinical trials studying Metastatic Hormone-sensitive Prostate Cancer. Study availability and eligibility vary by location and protocol.
21 public trials
5 recruiting studies
Metastatic Hormone-sensitive Prostate Cancer trial results
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683
- Conditions
- Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- Florida Cancer Specialists Sarasota, Florida, United States
- Start Midwest Grand Rapids, Michigan, United States
- Washington University School Of Medicine St Louis, Missouri, United States
- Perlmutter Cancer Center at NYU Langone Brooklyn Brooklyn, New York, United States
NCT06334120
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer
- Locations
-
- Many locations Multiple Locations, South Korea
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
- Locations
-
- Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company Cleveland, Ohio, United States
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
- Locations
-
- CH Bayonne Bayonne, France
- Institut Bergonié Bordeaux, France
- CHP Brest - Pasteur Brest, France
- Hôpital Henri-Mondor Créteil, France
NCT07795177
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- Universitythe First Affiliatedhospital of Anhuimedical Hefei, Anhui, China
Not yet recruiting
Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer
NCT07031258
- Conditions
- Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC), Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
Not specified
Active, not recruiting
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- University of California San Diego - Moores Cancer Center La Jolla, California, United States
- Saint Johns Cancer Institute Santa Monica, California, United States
- Rocky Mountain Cancer Centers Denver, Colorado, United States
- Yale Cancer Center New Haven, Connecticut, United States
Active, not recruiting
An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care
NCT06874114
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- Pentavere Toronto, Ontario, Canada
Active, not recruiting
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
NCT07344779
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
- Locations
-
- Many Locations Multiple Locations, Belgium
- Many Locations Multiple Locations, Finland
- Many Locations Multiple Locations, France
- Many Locations Multiple Locations, Germany